Last reviewed · How we verify
NCT07190976
The Value of EEG in Stroke Units
trial testing Routine EEG in Epilepsy in 100 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | Attikon Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 March 2024 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- Routine EEG
- Routine EEG
Conditions studied
- Epilepsy — all drugs for Epilepsy →
Sponsor
Attikon Hospital
Who can join
18 and older, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Τhe aim of the study is to investigate the role of EEG both in predicting epileptogenesis in patients with acute stroke and in detecting and clarifying the clinical significance of subclinical epileptic seizures in a stroke unit. More specifically, the performance of routine EEG in patients with ischemic or hemorrhagic stroke who are hospitalized in the Stroke Unit within the first days after the event, regardless of the presence of clinical indications, and the identification of risk factors for the early development of epilepsy in the course of these patients' disease constitute the central research question. The identification of patients with subclinical electroencephalographic seizures and the impact of such events on functional outcome, as well as their association with the development of epilepsy, are set as secondary research objectives.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07190976
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other Attikon Hospital trials
Trials by the same sponsor.
- NCT07425457 — Cryoneurolysis Prior to Total Knee Arthroplasty (CRYO-TKA Trial) · NA · recruiting
- NCT06646107 — Adherence to Mediterranean Diet in Type 1 Diabetes Initiating Minimed 780G: Glucose Metrics vs Insulin Metrics, is There · recruiting
- NCT06810700 — The Association Between Time in Range With Markers of Endothelial and Cardiovascular Function · not yet recruiting
- NCT06978387 — The Association Between Glycemic Metrics and Cardiovascular Markers in Patients With Type 1 Diabetes. · active not recruiting
- NCT06749613 — Digestive Enzyme Formulation Intervention in IBS Patients Who Previously Clinically Responded to Mediterranean LFD · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07190976 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Attikon Hospital
- Last refreshed: 24 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07190976.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing